ArticlePloS one2010
Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 69 citations in OpenAlex.
- Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts.Biomaterials · 2020Article
- Regulation of cardiomyocyte maturation during critical perinatal window.The Journal of physiology · 2020Review
- Imaging cellular pharmacokinetics of 18F-FDG and 6-NBDG uptake by inflammatory and stem cells.PloS one · 2018Article
- Transplantation of multipotent Isl1+ cardiac progenitor cells preserves infarcted heart function in mice.American journal of translational research · 2017Article
- Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction.Nature communications · 2016Article
- Pluripotent Stem Cells and Other Innovative Strategies for the Treatment of Ocular Surface Diseases.Stem cell reviews and reports · 2016Review
- Isolation of an ES-Derived Cardiovascular Multipotent Cell Population Based on VE-Cadherin Promoter Activity.Stem cells international · 2016Article
- Effects of different feeder layers on culture of bovine embryonic stem cell-like cells in vitro.Cytotechnology · 2014Article
- Regenerative medicine for the heart: perspectives on stem-cell therapy.Antioxidants & redox signaling · 2014Review
- Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease.Science (New York, N.Y.) · 2014Review
- Article
- Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells.Heart rhythm · 2013Article
- Enhanced mesenchymal stem cell survival induced by GATA-4 overexpression is partially mediated by regulation of the miR-15 family.The international journal of biochemistry & cell biology · 2013Article
- SWI/SNF in cardiac progenitor cell differentiation.Journal of cellular biochemistry · 2013Review
- Bioluminescence imaging: a shining future for cardiac regeneration.Journal of cellular and molecular medicine · 2013Review
- Stem cell therapy for chronic heart failure: an updated appraisal.Expert opinion on biological therapy · 2013Review
- Pluripotent stem cells for cardiac regeneration: overview of recent advances & emerging trends.The Indian journal of medical research · 2013Review
- The long-term differentiation of embryonic stem cells into cardiomyocytes: an indirect co-culture model.PloS one · 2013Article
- Induced pluripotent stem cell-derived cardiac progenitors differentiate to cardiomyocytes and form biosynthetic tissues.PloS one · 2013Article
- Inhibition of cardiomyocytes differentiation of mouse embryonic stem cells by CD38/cADPR/Ca2+ signaling pathway.The Journal of biological chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Stem cell transplantation holds great promise for the treatment of myocardial infarction injury. We recently described the embryonic stem cell-derived cardiac progenitor cells (CPCs) capable of differentiating into cardiomyocytes, vascular endothelium, and smooth muscle. In this study, we hypothesized that transplanted CPCs will preserve function of the infarcted heart by participating in both muscle replacement and neovascularization. Differentiated CPCs formed functional electromechanical junctions with cardiomyocytes in vitro and conducted action potentials over cm-scale distances. When transplanted into infarcted mouse hearts, CPCs engrafted long-term in the infarct zone and surrounding myocardium without causing teratomas or arrhythmias. The grafted cells differentiated into cross-striated cardiomyocytes forming gap junctions with the host cells, while also contributing to neovascularization. Serial echocardiography and pressure-volume catheterization demonstrated attenuated ventricular dilatation and preserved left ventricular fractional shortening, systolic and diastolic function. Our results demonstrate that CPCs can engraft, differentiate, and preserve the functional output of the infarcted heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.